Psychopharmacology of aggression in children and adolescents with autism: A critical review of efficacy and tolerability

Mihir S. Parikh, Alexander Kolevzon, Eric Hollander

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background: Autism is characterized by a clinical triad of symptoms that affect social, language, and behavioral domains. Aggression and self-injury may be associated symptoms of autism and can result in significant harm to those affected as well as marked distress for their families. The precise nature of the relationship between aggressive or self-injurious behavior (SIB) and autism remains unclear and as a result, these symptoms are treated with a broad range of pharmacological approaches. This review seeks to systematically and critically examine the evidence for the pharmacological management of aggression and SIB in children with autism spectrum disorders. Method: The entire PubMed database was searched for English language biomedical articles on clinical trials with medication in autism spectrum disorders. Studies were selected based on the following inclusion criteria: (1) randomized placebo-controlled trials; (2) a sample population that included children and adolescents; (3) at least one standardized assessment of aggression as a primary outcome measure of the study. Results: Twenty one trials with 12 medications were identified. Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone. Only risperidone and methylphenidate demonstrate results that have been replicated across at least two studies. Conclusions: Although many medications have been studied under placebo-controlled conditions, few produce significant improvement. Additional placebo-controlled trials are needed to increase the number of therapeutic options available in the treatment of aggression in autism.

Original languageEnglish (US)
Pages (from-to)157-178
Number of pages22
JournalJournal of Child and Adolescent Psychopharmacology
Volume18
Issue number2
DOIs
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Psychopharmacology
Autistic Disorder
Aggression
Placebos
Self-Injurious Behavior
Methylphenidate
tianeptine
Risperidone
Language
Outcome Assessment (Health Care)
Pharmacology
Naltrexone
Clonidine
PubMed
Randomized Controlled Trials
Clinical Trials
Databases
Wounds and Injuries
Therapeutics
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Psychopharmacology of aggression in children and adolescents with autism : A critical review of efficacy and tolerability. / Parikh, Mihir S.; Kolevzon, Alexander; Hollander, Eric.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 18, No. 2, 01.04.2008, p. 157-178.

Research output: Contribution to journalArticle

@article{cf4f82999beb4c8b96162a28cf192d16,
title = "Psychopharmacology of aggression in children and adolescents with autism: A critical review of efficacy and tolerability",
abstract = "Background: Autism is characterized by a clinical triad of symptoms that affect social, language, and behavioral domains. Aggression and self-injury may be associated symptoms of autism and can result in significant harm to those affected as well as marked distress for their families. The precise nature of the relationship between aggressive or self-injurious behavior (SIB) and autism remains unclear and as a result, these symptoms are treated with a broad range of pharmacological approaches. This review seeks to systematically and critically examine the evidence for the pharmacological management of aggression and SIB in children with autism spectrum disorders. Method: The entire PubMed database was searched for English language biomedical articles on clinical trials with medication in autism spectrum disorders. Studies were selected based on the following inclusion criteria: (1) randomized placebo-controlled trials; (2) a sample population that included children and adolescents; (3) at least one standardized assessment of aggression as a primary outcome measure of the study. Results: Twenty one trials with 12 medications were identified. Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone. Only risperidone and methylphenidate demonstrate results that have been replicated across at least two studies. Conclusions: Although many medications have been studied under placebo-controlled conditions, few produce significant improvement. Additional placebo-controlled trials are needed to increase the number of therapeutic options available in the treatment of aggression in autism.",
author = "Parikh, {Mihir S.} and Alexander Kolevzon and Eric Hollander",
year = "2008",
month = "4",
day = "1",
doi = "10.1089/cap.2007.0041",
language = "English (US)",
volume = "18",
pages = "157--178",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Psychopharmacology of aggression in children and adolescents with autism

T2 - A critical review of efficacy and tolerability

AU - Parikh, Mihir S.

AU - Kolevzon, Alexander

AU - Hollander, Eric

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Background: Autism is characterized by a clinical triad of symptoms that affect social, language, and behavioral domains. Aggression and self-injury may be associated symptoms of autism and can result in significant harm to those affected as well as marked distress for their families. The precise nature of the relationship between aggressive or self-injurious behavior (SIB) and autism remains unclear and as a result, these symptoms are treated with a broad range of pharmacological approaches. This review seeks to systematically and critically examine the evidence for the pharmacological management of aggression and SIB in children with autism spectrum disorders. Method: The entire PubMed database was searched for English language biomedical articles on clinical trials with medication in autism spectrum disorders. Studies were selected based on the following inclusion criteria: (1) randomized placebo-controlled trials; (2) a sample population that included children and adolescents; (3) at least one standardized assessment of aggression as a primary outcome measure of the study. Results: Twenty one trials with 12 medications were identified. Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone. Only risperidone and methylphenidate demonstrate results that have been replicated across at least two studies. Conclusions: Although many medications have been studied under placebo-controlled conditions, few produce significant improvement. Additional placebo-controlled trials are needed to increase the number of therapeutic options available in the treatment of aggression in autism.

AB - Background: Autism is characterized by a clinical triad of symptoms that affect social, language, and behavioral domains. Aggression and self-injury may be associated symptoms of autism and can result in significant harm to those affected as well as marked distress for their families. The precise nature of the relationship between aggressive or self-injurious behavior (SIB) and autism remains unclear and as a result, these symptoms are treated with a broad range of pharmacological approaches. This review seeks to systematically and critically examine the evidence for the pharmacological management of aggression and SIB in children with autism spectrum disorders. Method: The entire PubMed database was searched for English language biomedical articles on clinical trials with medication in autism spectrum disorders. Studies were selected based on the following inclusion criteria: (1) randomized placebo-controlled trials; (2) a sample population that included children and adolescents; (3) at least one standardized assessment of aggression as a primary outcome measure of the study. Results: Twenty one trials with 12 medications were identified. Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone. Only risperidone and methylphenidate demonstrate results that have been replicated across at least two studies. Conclusions: Although many medications have been studied under placebo-controlled conditions, few produce significant improvement. Additional placebo-controlled trials are needed to increase the number of therapeutic options available in the treatment of aggression in autism.

UR - http://www.scopus.com/inward/record.url?scp=42549141631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549141631&partnerID=8YFLogxK

U2 - 10.1089/cap.2007.0041

DO - 10.1089/cap.2007.0041

M3 - Article

C2 - 18439113

AN - SCOPUS:42549141631

VL - 18

SP - 157

EP - 178

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 2

ER -